Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06050928 · ClinicalTrials.gov registry record · Phase 1
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
A Phase 1 study of Chronic Inducible Urticaria, sponsored by Escient Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 15
- Study locations
NCT06050928 is a Phase 1 study of Chronic Inducible Urticaria that has completed, run by Escient Pharmaceuticals. The registered enrollment target is 33 participants, below the 226-participant average among 4 other Chronic Inducible Urticaria trials with a reported enrollment target (85% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT06050928, a Phase 1 study of Chronic Inducible Urticaria, has completed, sponsored by Escient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 15
- Study locations
Study Summary
This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.
Conditions Studied
Interventions
- DRUG Oral EP262
Study Locations (15)
Other
- Innovaderm Research Inc. - Montreal
- Gordon Sussman Clinical Research Inc. - North York
- Institut fur Allergieforschung Charite - Universitatsmedizin Berlin - Berlin
- Hospital del Mar - Barcelona
- Hospital Arnau de Vilanova - Valencia
Florida
- Advanced Clinical Research Institute - Tampa
Idaho
- Treasure Valley Medical Research - Boise
Kentucky
- Allergy & Asthma Specialists, P.S.C. - Owensboro
Maryland
- Johns Hopkins University - Baltimore
Ohio
- Bernstein Clinical Research Center, LLC - Cincinnati
Pennsylvania
- Allergy and Clinical Immunology Associates - Pittsburgh
South Carolina
- National Allergy and Asthma Research, LLC. - North Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2024-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06050928
The ClinicalTrials.gov registry entry for NCT06050928 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 226-participant average among 4 other Chronic Inducible Urticaria trials with a reported enrollment target (85% lower). The listed sponsor is Escient Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inducible Urticaria appearing as the primary indexed condition, and to 1 intervention - of which Oral EP262 is the first listed.
NCT06050928 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, Idaho.
Frequently Asked Questions
What is clinical trial NCT06050928 about?
NCT06050928 is a clinical study titled "Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria". This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.
What is the current status of trial NCT06050928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2023-08-30. Estimated completion is 2024-10-22.
What conditions does trial NCT06050928 study?
This clinical trial studies the following conditions: Chronic Inducible Urticaria.
What interventions are being tested in trial NCT06050928?
The interventions under investigation include: Oral EP262 (DRUG).
Who is sponsoring clinical trial NCT06050928?
This trial is sponsored by Escient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06050928 being conducted?
This trial has 15 study locations across Florida, Idaho, Kentucky, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inducible Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
RECRUITING · Phase 3
-
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
RECRUITING · Phase 2
-
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
ACTIVE NOT RECRUITING · Phase 3
-
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.